Sanofi is shelling out $1.15 billion to acquire Vicebio, a startup with a pipeline of respiratory vaccine candidates and a platform technology that will support the pharmaceutical giant’s ambitions to ...
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus (RSV) pipeline beyond mRNA. The French ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — Sanofi on Tuesday said it would buy the vaccine-focused biotech ...
Lara Herrero receives funding from the National Health and Medical Research Council. As winter settles over Australia, it’s not just the drop in temperature we notice – there’s also a sharp rise in ...
Monoclonal antibodies that specifically recognize the hMPV nucleoprotein (NP) are available for scientific research and clinical diagnostic applications. To support the research community, Creative ...
NEW YORK, NY, UNITED STATES, July 21, 2025 / EINPresswire.com / -- Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback